Comparison of Cisplatinum/Paclitaxe concurrent radiotherapy for advanced nasopharyngeal carcinoma
10.3760/cma.j.issn.1008-6706.2015.09.040
- VernacularTitle:多西他赛/顺铂联合放射疗法同步治疗局部晚期鼻咽癌的疗效比较
- Author:
Xiaoshan XUAN
;
Ping TIAN
;
Hongshou XIE
- Publication Type:Journal Article
- Keywords:
Nasopharyngeal neoplasms;
Cisplatinum;
Paclitaxe;
Radiation therapy
- From:
Chinese Journal of Primary Medicine and Pharmacy
2015;22(9):1394-1397
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the acute side effects and recent therapeutical effect of cisplatinum/paclitaxe concurrent radiotherapy for patients with advanced nasopharyngeal carcinoma.Methods 87 patients with advanced nasopharygeal carcinoma were enrolled.According to the treatment,87 patients were divided into paclitaxe group (groupA,n =43) and cisplatinum group (group B,n =44).The two groups were treated with 6MV-X ray for radiotherapy.The prescription dose of radiation therapy was PGTV,PGTVnd 6 996 cGy/33F,PTV1 6 006 cGy/33F,PTV2 5 096 cGy/28F.The two groups began concurrent chemotherapy in radiotherapy,specific method:group A paclitaxe 30mg/m2,1 time a week,until the end of radiotherapy,group B cisplatinum 80 ～100 mg/m2,every 21 days.Results The recent therapeutical effect of nasopharyngeal lesions and lymph nodes of neck for group A and group B were 88.4％ and 86.4％ (x2 =0.079,P =0.778),88.4％ and 88.6％ (x2 =0.000,P =1.000),respectively.But the occurrence rate of group B ' oral mucosa reaction (x2 =4.295,P =0.038) and gastrointestinal reaction (x2 =4.482,P =0.028) were higher than that of group A.Conclusion Treated with cisplatin in advanced nasopharyngeal carcinoma after radical radiotherapy combined with docetaxel is similar,and the side effect is low,the tolerance of patients is good,curative effect is satisfied.
